Cross-Cultural Validation of the RECAP of Atopic Eczema Questionnaire in a Swedish Population
Acta Dermato-Venereologica · 2024
DOI: 10.2340/actadv.v104.38889 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Acta Dermato-Venereologica, 2024. Verfasst von Gunnthorunn Sigurdardottir und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venereology in Östergötland, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Swede…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Severity of Illness Index, Patient Reported Outcome Measures. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
A Swedish translation of the patient-reported outcome measure for assessing long-term control of atopic dermatitis, Recap of atopic eczema (RECAP), has not been validated. Cross-cultural translation and multi-centre validation of the translated RECAP questionnaire were therefore performed. Disease severity was assessed using the validated Investigator Global Assessment Scale for atopic dermatitis (vIGA-ADTM). The Swedish RECAP was completed by 208 individuals aged 16 years or older with a median age of 36 years (interquartile range [IQR] 27–48). The participants considered the questionnaire suitable for assessing eczema control. The median RECAP score (range 0–28) was 12 (IQR 5–19). The mean and median vIGA-ADTM scores (range 0–4) were 2 (standard deviation [SD] 2) and 3 (IQR 2–4), respectively. A correlation between RECAP and the vIGA-ADTM was observed (p < 0.001). There was no significant change in scores for participants who answered the questionnaire twice within 14 days. Over time, improved or worsened eczema, as evaluat-ed by vIGA-ADTM, affected RECAP scores significantly (p < 0.001). The study suggests that RECAP can assess AD control in a Swedish clinical setting and shows -acceptable reliability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Dermatology and Venereology in Östergötland, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. gunnthorunn.sigurdardottir@liu.se.
- Department of Dermatology and Venereology, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Division of Dermatology and Venereology, Department of Medicine Solna, Karoli…
- Department of Dermatology and Venereology in Östergötland, and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
- Division of Dermatology and Venereology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Dermatology, Karolinska University Hospital, Stockholm, Sweden.
- Vasakliniken Dermatology Clinic, Gothenburg, Sweden.
- Dermatology, Karolinska University Hospital, Stockholm, Sweden.
Zitieren
APA
Sigurdardottir, G., Alsterholm, M., Andersson, C. D., Bradley, M., Sandström Falk, M., Johansson, E. K., Lundqvist, M., Sonesson, A., Svensson, Å., Theodosiou, G., Vrang, S., & Von Kobyletzki, L. B. (2024). Cross-Cultural Validation of the RECAP of Atopic Eczema Questionnaire in a Swedish Population. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v104.38889
Vancouver
Sigurdardottir G, Alsterholm M, Andersson CD, Bradley M, Sandström Falk M, Johansson EK, et al. Cross-Cultural Validation of the RECAP of Atopic Eczema Questionnaire in a Swedish Population. Acta Dermato-Venereologica. 2024. doi:10.2340/actadv.v104.38889
BibTeX
@article{Sigurdardottir2024,
author = {Sigurdardottir, Gunnthorunn and Alsterholm, Mikael and Andersson, Chris D and Bradley, Maria and Sandström Falk, MariHelen and Johansson, Emma K and Lundqvist, Maria and Sonesson, Andreas and Svensson, Åke and Theodosiou, Grigorios and Vrang, Sophie and Von Kobyletzki, Laura B},
title = {Cross-Cultural Validation of the RECAP of Atopic Eczema Questionnaire in a Swedish Population},
journal = {Acta Dermato-Venereologica},
year = {2024},
doi = {10.2340/actadv.v104.38889}
}
EUVIMED